Clearance Summary
RELiZORB® received FDA 510(k) clearance under submission number K232784, sponsored by Alcresta Therapeutics, Inc.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Gastroenterology, Urology review panel. The statutory decision date of record is 2023-12-21.
- Submission: K232784
- Applicant / Sponsor: Alcresta Therapeutics, Inc.
- Clearance pathway: Traditional
- Review panel: Gastroenterology, Urology
- Device class: Class II
- Regulation citation: 21 CFR 876.5985
- Decision date: 2023-12-21
Classification & Regulation
This clearance is catalogued under FDA product code PLQ and 21 CFR 876.5985, within the Gastroenterology, Urology review panel as a Class II device.